Karyopharm Therapeutics Inc (KPTI) insider trading

Every open-market stock purchase and sale by Karyopharm Therapeutics Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • Kristin Abate (C-suite exec) and 1 other sold $3.5K in the last 90 days.
  • Last insider buy: Garen G Bohlin (Insider), $50K, 3 years ago.

Last 12 months: insiders bought $0 (0 buys) and sold $351K (21 sales). Last close $0.42 on Oct 21, 2026.

Recent KPTI insider trades

DateInsiderTradeValue
Oct 16, 2026Kristin Abate (C-suite exec)Sold$1.6K
Oct 1, 2026Kristin Abate (C-suite exec)Sold$450
Sep 1, 2026Kristin Abate (C-suite exec)Sold$38
Jul 28, 2026Stuart Poulton (C-suite exec)Sold$1.3K
May 21, 2026Chen Schor (Insider)Bought (not open market)—
May 21, 2026Zhen Su (Insider)Bought (not open market)—
May 21, 2026Christy J. Oliger (Insider)Bought (not open market)—
May 21, 2026Garen G Bohlin (Insider)Bought (not open market)—
May 21, 2026Barry E Greene (Insider)Bought (not open market)—
May 21, 2026Deepika Pakianathan (Insider)Bought (not open market)—
May 14, 2026Richard A. Paulson (CEO)Sold$20.9K
May 14, 2026Reshma Rangwala (C-suite exec)Sold$3.9K
May 14, 2026Stuart Poulton (C-suite exec)Sold$3.8K
May 14, 2026Sohanya Roshan Cheng (C-suite exec)Sold$3.1K
May 14, 2026Michael Mano (C-suite exec)Sold$2.5K
May 14, 2026Kristin Abate (C-suite exec)Sold$504
May 13, 2026Kristin Abate (C-suite exec)Bought (not open market)—
May 13, 2026Sohanya Roshan Cheng (C-suite exec)Bought (not open market)—
May 13, 2026Michael Mano (C-suite exec)Bought (not open market)—
May 13, 2026Richard A. Paulson (CEO)Bought (not open market)—
May 13, 2026Reshma Rangwala (C-suite exec)Bought (not open market)—
May 13, 2026Stuart Poulton (C-suite exec)Bought (not open market)—
Apr 21, 2026Reshma Rangwala (C-suite exec)Sold$4K
Mar 2, 2026Richard A. Paulson (CEO)Sold$116K
Mar 2, 2026Stuart Poulton (C-suite exec)Sold$48K

Who's trading KPTI

Get free alerts when an insider at Karyopharm Therapeutics Inc files a new trade →